Table 2.

Clinical characteristics of PSMA-TB in 25 patients

	Age (y)	PSA(ng/ml)	SUVmax PSMA-PET	Number of lesions	Lesion-size Short*Long (cm) PSMA-PET	PSMA-TB (Gleason)	Cancer tissue ratio (%)	TRUS-GB (Gleason)	Pathological outcome after RP (Gleason)
1	78	100.00	29.32	1	2.88*3.78	PCa, 3 + 4 = 7	80		RP, PCa3 + 4 = 7
2	64	18.54	13.99	1	1.15*1.93	PCa, 3 + 4 = 7	35	BPH	RP, PCa4 + 3 = 7
3	85	8.85	11.48	1	0.88*0.97	PCa, 3 + 4 = 7	50		N
4	89	14.76	20.52	1	1.15*2.21	PCa, 3 + 3 = 6	20	BPH	N
5	64	129.50	28.16	3	0.98*1.50	PCa, 4 + 4 = 8	80		RP, PCa4 + 4 = 8
6	70	52.05	15.20	1	1.10*1.50	PCa, 4 + 4 = 8	80		RP, PCa4 + 4 = 8
7	82	39.00	11.56	2	0.70*1.17	PCa, 4 + 3 = 7	20		RP, PCa4 + 4 = 8
8	75	15.26	11.91	1	0.59*0.74	PCa, 4 + 3 = 7	70		RP, PCa4 + 3 = 7
9	57	43.91	22.45	2	1.07*1.50	PCa, 4 + 3 = 7	50		RP, PCa4 + 3 = 7
10	85	32.67	34.93	1	2.16*3.06	PCa, 4 + 4 = 8	100		N
11	80	12.98	9.97	2	0.63*1.26	BPH		PCa, 3 + 4 = 7	RP, PCa3 + 4 = 7
12	68	36.24	12.90	1	0.52*0.64	BPH		PCa,4 + 3 = 7	RP, PCa4 + 3 = 7
13	63	98.86	30.55	2	2.00*3.20	PCa, 4 + 3 = 7	90		N
14	55	9.899	30.99	1	0.78*1.48	PCa, 4 + 4 = 8	20		N
15	85	15.37	10.18	2	0.88*1.20	PCa, 3 + 4 = 7	30		N
16	65	6.31	13.46	1	0.49*1.05	PCa, 4 + 4 = 8	50		RP, PCa4 + 4 = 8
17	78	79.60	60.69	3	3.60*5.90	PCa, 4 + 4 = 8	50		RP, PCa4 + 4 = 8
18	90	17.98	20.65	2	0.93*1.78	PCa, 4 + 4 = 8	50		N
19	73	35.60	8.73	1	1.64*2.36	PCa, 4 + 3 = 7	100		N,APR
20	72	31.00	62.40	1	2.11*2.86	PCa, 4 + 3 = 7	90		RP,PCa4 + 4 = 8
21	83	30.97	17.99	2	1.41*1.83	PCa, 3 + 4 = 7	50		N
22	75	96.04	44.90	2	1.93*4.15	PCa, 4 + 4 = 8	70		N
23	75	38.00	19.40	2	0.79*1.37	PCa, 4 + 5 = 9	50		RP, PCa4 + 5 = 9
24	76	57.67	9.63	1	0.32*0.47	BPH		BPH	TURP
25	74	42.82	10.75	2	0.33*0.66	BPH		BPH	TURP

RP, radical prostatectomy; BPH, benign prostate hyperplasia; N, no operation; APR, abdomino-perineal resection with rectal cancer prior to prostate biopsy; TURP, transurethral resection of the prostate